Related Experiment Video
Updated: Jun 10, 2025
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
Application and challenge of HER2DX genomic assay in HER2+ breast cancer treatment
Shujuan Ma1,2, Yan Zhou1,2, Dandan Ma1,2
1Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University Chongqing 400038, China.
Abstract:
HER2-positive breast cancer is highly aggressive, with a significant risk of recurrence and metastasis, leading to a poor prognosis. While most early-stage HER2-positive breast cancer patients benefit from combining trastuzumab monoclonal antibody with chemotherapy, the therapeutic response to various drug combinations varies across the HER2+ patient population. Therefore, predicting the prognosis and treatment response of HER2+ breast cancer patients to specific regimens is crucial for selecting appropriate precision individualized therapies. HER2DX is the first genomic tool designed to guide the treatment of HER2+ breast cancer patients. The three scores provided by HER2DX inform the entire treatment process, including predicting survival outcomes, recurrence, metastasis, and treatment responses like Pathological Complete Response Rate (pCR). It offers recommendations on follow-up intervals, treatment plans, and the duration of drug therapy. This review examines the literature and analyzes studies applying HER2DX to guide the comprehensive treatment and predict prognosis in HER2+ breast cancer patients, aiming to promote the widespread use of HER2DX in individualized treatment.
Insights
HER2DX is a genomic tool that predicts prognosis and treatment response in HER2-positive breast cancer patients. This review supports its use for personalized therapy and improved outcomes.
Area of Science:
- Oncology
- Genomics
- Precision Medicine
Background:
- HER2-positive breast cancer is aggressive, with variable treatment responses.
- Predicting prognosis and therapeutic outcomes is vital for personalized treatment strategies.
Purpose of the Study:
- To review the literature on the application of the HER2DX genomic tool.
- To analyze studies using HER2DX for comprehensive treatment guidance and prognosis prediction in HER2-positive breast cancer.
- To promote the adoption of HER2DX in individualized cancer care.
Main Methods:
- Literature review and analysis of studies utilizing the HER2DX genomic tool.
- Examination of HER2DX's role in predicting survival, recurrence, metastasis, and pathological complete response (pCR).
Main Results:
- HER2DX provides three scores to guide treatment decisions.
- The tool aids in predicting patient outcomes and response to specific drug combinations.
- HER2DX assists in tailoring follow-up intervals, treatment plans, and therapy duration.
Conclusions:
- HER2DX is the first genomic tool specifically for guiding HER2-positive breast cancer treatment.
- The tool enhances precision medicine by informing prognosis and treatment response.
- Widespread use of HER2DX can optimize individualized therapeutic approaches for better patient management.
More Related Videos
11:34Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
